Altamira Therapeutics Ltd.
CYTOF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001601936
No open-market purchases or sales by Altamira Therapeutics Ltd. insiders were filed in the last 90 days; 1 institution reported holding it in 13F filings for Q2 2026, worth $0 in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Altamira Therapeutics Ltd. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 4 | 3 | −1 |
| Shares | 7.68K | 1.68K | −6.00K (−78.2%) |
| Value | $26.7K | $3.47K | −$23.3K (−87.0%) |
New holders (1)
Institutions that held Altamira Therapeutics Ltd. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| LRI Investments, LLC | 1 | $2 | 0.00% |
Sold out (2)
Institutions that held Altamira Therapeutics Ltd. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| UBS Group AG | 6,814 | $23.7K |
| Wells Fargo & Company | 1 | $3 |